Predicting long-term disease control in transplant-ineligible patients with multiple myeloma

Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials...

Descripción completa

Detalles Bibliográficos
Autores: Rodriguez-Otero, Paula|||0000-0001-5236-7785, Mateos, M. V|||0000-0003-2390-1218, Martínez-López, Joaquín|||0000-0001-7908-0063, Hernández, Miguel Teodoro|||0000-0002-6576-7881, Ocio, Enrique M.|||0000-0002-5765-0085, Rosiñol, Laura|||0000-0002-2534-9239, Martínez Martínez, Rafael, Teruel, Ana Isabel|||0000-0003-1559-7607, Gutierrez, Norma|||0000-0001-5834-9510, Bargay, Joan|||0000-0002-6739-3916, Bengoechea, Enrique, González, Yolanda, Perez de Oteyza, Jaime|||0000-0002-8338-2037, Gironella, Mercedes|||0000-0002-8106-8909, Nuñez-Córdoba, Jorge, Encinas, C|||0000-0002-9001-9754, Martín, Jesús, Cabrera, Carlos, Palomera, Luis|||0000-0003-0359-7191, De Arriba, Felipe|||0000-0002-4451-1318, Cedena, María Teresa|||0000-0001-5851-3720, Puig, Noemí|||0000-0001-7535-3861, Oriol, Albert|||0000-0001-6804-2221, Paiva, Bruno|||0000-0003-1977-3815, Bladé Creixenti, Juan|||0000-0002-4563-3405, Lahuerta, J. J.|||0000-0002-3393-9570, San Miguel, Jesús F.
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:236895
Acceso en línea:https://ddd.uab.cat/record/236895
https://dx.doi.org/urn:doi:10.1038/s41408-019-0176-x
Access Level:acceso abierto
Palabra clave:Aged
Female
Humans
Male
Monoclonal Gammopathy of Undetermined Significance
Multiple Myeloma
Descripción
Sumario:Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) ≥ 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb ≥ 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.

Similares en LA Referencia